A single centre, proof-of-concept clinical study for SM-88 in advanced metastatic cancer patients

Trial Profile

A single centre, proof-of-concept clinical study for SM-88 in advanced metastatic cancer patients

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs SM 88 (Primary)
  • Indications Advanced breast cancer; Cancer
  • Focus First in man; Proof of concept; Therapeutic Use
  • Sponsors Tyme Technologies
  • Most Recent Events

    • 06 Nov 2017 Results from women with metastatic breast cancer (n = 14) presented in a Tyme Technologies media release.
    • 19 Oct 2017 Results published in a Tyme Technologies media release.
    • 07 Sep 2017 Long-term updated results published in a Tyme Technologies Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top